CSTL Oct 2024 30.000 call

OPR - OPR Delayed Price. Currency in USD

Add to watchlist

1.4000

0.0000

(0.00%)

At close: 03:45PM EDT

Loading interactive chart...

Business Wire
New Data at ASTRO 2024 Shows Castle Biosciences’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma
FRIENDSWOOD, Texas, September 27, 2024--Castle will share data at ASTRO24 showing its DecisionDx-SCC test can provide impactful risk stratification in high-risk SCC patient sub-populations.
Business Wire
New Data at AFS 2024 Demonstrates the Strength of Castle Biosciences’ TissueCypher® Test in Independently Predicting Risk of Developing Esophageal Cancer, Guiding Risk-Aligned Management Decisions for Patients with Barrett’s Esophagus
FRIENDSWOOD, Texas, September 23, 2024--Castle to share data at AFS 2024 showing TissueCypher independently predicts risk of progression to esophageal cancer in Barrett’s esophagus patients.
Business Wire
Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Named Arizona Bioscience Leader of the Year
PHOENIX & FRIENDSWOOD, Texas, September 16, 2024--Castle Biosciences' COO, Kristen Oelschlager, R.N., has been named the 2024 Jon W. McGarity Arizona Bioscience Leader of the Year by AZBio.